Toronto-based 1DegreeBio closes Series B funding round with Macmillan Digital Science
“1DegreeBio Inc., the largest independent review website for research-grade antibodies and related life science products has closed a Series B round of funding, led by Macmillan Digital Science Limited. Philip Armstrong, CEO of Jovian Capital Corporation, and 1DegreeBio senior management also participated in the round. The funding announcement follows a year of exceptional growth by 1DegreeBio, which has increased its user base from 23,000 to more than 75,000 users, and increased its product database from 400,000 products to more than 800,000 since July 2011... Alex Hodgson, Managing Director, 1DegreeBio [said,] ‘Our growth has been even greater than anticipated; in the last year we've tripled our user base and more than doubled our product listings. It would not have been possible without the passion of the 1DegreeBio team, the support of our funders and the scientific community that has stood behind us from day one.’ 1DegreeBio is among Digital Science's portfolio companies, which also include SureChem, Labtiva, BioData, BioRAFT, figshare and Symplectic. Together they support Digital Science's mandate to provide cutting edge software and technology to make scientific research more efficient. Following on the launch of its Epigenetics Portal on June 4, 1DegreeBio will be launching a series of other specialized portals to support specific research areas over the next few months. The coming year will also see expansion into other life science product types and services, in addition to conducing new market research around the life science community. ‘It's an exciting time at 1DegreeBio - from new collaborations and outreach initiatives to new tools and expansion plans,’ said Hodgson. ‘This next year is going to knock your socks off.’"